



CL/V-20676/P1/CGV1764/CIP/DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: NICOLSON, PAUL C., ET AL) ART UNIT: 1511
SERIAL NO.: 08/682,452) EXAMINER: NOT YET
FILED ON: 07/17/96) DETERMINED
FOR: EXTENDED WEAR)
OPHTHALMIC LENS)

#7
TRACEY BEN.
4.23.97
APR 10 1997
MAIL ROOM

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelop addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Ann BRAYLEY Date: 3/21/97 Signature: Ann Brayley
(Type or print name of party mailing paper)

Assistant Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. 1.56, Applicants wish to call the Examiner's attention to the references cited on the attached Form PTO-1449. Copies of these references are enclosed herewith.

This Statement is being filed in accordance with:

X
_____ 37 C.F.R. 1.97(b), wherein an information disclosure statement is considered timely filed if (1) within three months of the filing of a national application, (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or (3) before the mailing date of a first Office action on the merits.



37 C.F.R. 1.97(c), wherein an information disclosure statement shall be considered by the Office if filed after the 37 C.F.R. 1.97(b) time period, but before the mailing date of either: (1) a final action under 37 C.F.R. 1.113 or (2) a notice of allowance under 37 C.F.R. 1.311, whichever occurs first, provided the statement is accompanied by either a certification or a 37 C.F.R. 1.17(p) fee. **The Commissioner is hereby authorized to charge to Deposit Account No. 19-0134 the \$220 fee required in a 37 C.F.R. 1.17(p) fee.**

Consideration of the foregoing references in relation to this application, including an indication thereof by marking each of the cited references in the column entitled "Examiner's Initial", is respectfully requested.

The Commissioner is hereby authorized to charge fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 19-0134.

Please address all correspondence to Michael W. Glynn, Novartis Corporation, Patent and Trademark Department, 59 Route 10, East Hanover, NJ 07936-1080. Please address all telephone calls to the undersigned at the number given below.

Respectfully submitted,

R. Scott Meece
Registration No. 34,675
Attorney for Applicants

Date: 3/21/97

Novartis Corporation
Patent & Trademark Department
59 Route 10
East Hanover, NJ 07936-1080
(770) 418-3054